Hepatitis C Virus

Tibotec files application to start phase 1 trial for HCV inhibitor on behalf of Medivir

Published in Vaccine Weekly, January 24th, 2007

Tibotec Pharmaceuticals Inc, on behalf of the Medivir (MVIRB) and Tibotec collaborative drug discovery project on hepatitis C virus (HCV), has filed an application with a European regulatory authority to commence the first phase 1 clinical trial of an HCV NS3/4A protease inhibitor.

The trial is estimated to begin during the first quarter of 2007. The collaboration was initiated in November 2004. This milestone triggers a payment of EUR 2.5 million (US$3.25 million) to Medivir.

"It is extremely pleasing that this project with joint resources and efforts now stands at the threshold of clinical trials. We look forward to 2007 and our continued...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2007-01-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry